Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3901409 | Urology | 2012 | 6 Pages |
Abstract
A CCR at the ERP disease site is associated with a greater likelihood of relapse compared with a PCR, underscoring the limitations of radiographic imaging after chemotherapy in detecting microscopic residual disease and need for rigorous monitoring of patients observed after a CCR. Furthermore, until more accurate clinical predictors of ERP histologic features are identified, we advocate for complete surgical resection of all sites of residual disease, when feasible.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Timothy A. Masterson, Brett S. Carver, Bobby Shayegan, Darren R. Feldman, Robert J. Motzer, George J. Bosl, Joel Sheinfeld,